Voyager Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Voyager Therapeutics, a biotechnology firm focused on gene therapy and neurology, announced its participation in several upcoming investor conferences. Key events include:

• SVB Securities Global Biopharma Conference (Virtual) – February 16, 2023, at 1:40 p.m. ET
• Cowen 43rd Annual Health Care Conference, Boston, MA – March 6, 2023, at 10:30 a.m. ET
• Oppenheimer 33rd Annual Healthcare Conference (Virtual) – March 13, 2023, at 8:40 a.m. ET

Webcasts of these sessions will be available on Voyager's website for 30 days post-event. The company utilizes its TRACER™ AAV capsid discovery platform to enhance gene therapy delivery and addresses neurological disorders.

CAMBRIDGE, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences:

• SVB Securities Global Biopharma Conference (Virtual) – Company presentation, February 16, 2023, 1:40 p.m. ET
• Cowen 43rd Annual Health Care Conference, Boston, MA – Panel discussion, March 6, 2023, 10:30 a.m. ET
• Oppenheimer 33rd Annual Healthcare Conference (Virtual) – Company presentation, March 13, 2023, 8:40 a.m. ET
  

The sessions may be accessed from the Investors section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on Voyager’s website for at least 30 days.

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is a biotechnology company dedicated to breaking through barriers in gene therapy and neurology. The potential of both disciplines has been constrained by delivery challenges; Voyager is leveraging cutting-edge expertise in capsid discovery and deep neuropharmacology capabilities to address these constraints. Voyager’s TRACER^TM AAV capsid discovery platform has generated novel capsids with high target delivery and blood-brain barrier penetration at low doses, potentially addressing the narrow therapeutic window associated with conventional gene therapy delivery vectors. This platform is fueling alliances with Pfizer Inc., Novartis and Neurocrine Biosciences as well as multiple programs in Voyager’s own pipeline. Voyager’s pipeline includes wholly-owned and collaborative preclinical programs in Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and Friedreich’s Ataxia, each with validated targets and biomarkers to enable a path to rapid potential proof-of-biology. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. 

Contacts

Investors
Andrew Funderburk
afunderburk@kendallir.com

Media
Peg Rusconi
prusconi@vergescientific.com

FAQ

What investor conferences will VYGR participate in February 2023?

VYGR will participate in the SVB Securities Global Biopharma Conference on February 16, 2023.

When is the Cowen 43rd Annual Health Care Conference for VYGR?

The Cowen 43rd Annual Health Care Conference is scheduled for March 6, 2023.

What is the date for the Oppenheimer Healthcare Conference for VYGR?

The Oppenheimer 33rd Annual Healthcare Conference will take place on March 13, 2023.

Where can I access VYGR's investor conference webcasts?

You can access the webcasts on Voyager Therapeutics' official website.

What is Voyager Therapeutics' focus in the biotechnology sector?

Voyager Therapeutics focuses on gene therapy and neurology, aiming to overcome delivery challenges.